The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: A systematic review

Insights into Imaging

Volumn 4, Issue 2, 2013, Pages 163-175

  Lobbes, M B I ^a   Prevos, R ^a   Smidt, M ^a   Tjan Heijnen, V C G ^a   van Goethem, M ^b   Schipper, R ^a   Beets Tan, R G ^a   Wildberger, J E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Breast cancer; MRI; Neoadjuvant chemotherapy; Residual disease

Indexed keywords

EID: 84875647956     PISSN: None     EISSN: 18694101     Source Type: Journal    
DOI: 10.1007/s13244-013-0219-y     Document Type: Review

References (54)

1. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97: 188-194.
2. Kong X, Moran MS, Zhang N et al (2011) Meta-analysis confirms achieving pathological complete respons after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Canc 47: 2084-2090.
3. Chagpar AB, Middleton LP, Sahin AA et al (2006) Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumour size in patients treated with neoadjuvant chemotherapy. Ann Surg 243: 257-264.
4. van Goethem M, Schelfout K, Kersschot E et al (2007) MR mammography is useful in the preoperative locoregional staging of breast carcinomas with extensive intraductal component. Eur J Radiol 62: 273-282.
5. Drew PJ, Chatterjee S, Turnbull LW et al (1999) Dynamic contrast enhanced magnetic resonance imaging of the breast is superior to triple assessment for the pre-operative detection of multifocal breast cancer. Ann Surg Oncol 6: 599-603.
6. Yuan Y, Chen X, Liu S, Shen K (2010) Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. Am J Roentgenol 195: 260-268.
7. Wu LM, Hun JN, Gu HY et al (2012) Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat 135: 17-28.
8. Marinovich ML, Sardanelli F, Ciatto S et al (2012) Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast 21: 669-677.
9. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
10. Abraham DC, Jones RC, Jones SE et al (1996) Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78: 91-100.
11. Esserman L, Kaplan E, Partridge S et al (2001) MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8: 549-559.
12. Rieber A, Brambs HJ, Gabelmann A et al (2002) Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12: 1711-1719.
13. Partridge SC, Gibbs JE, Lu Y et al (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol 179: 1193-1199.
14. Cheung Y, Chen S, Su M et al (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Canc Res Treat 78: 51-58.
15. Denis F, Desbiez-Bourcier AV, Chapiron C et al (2004) Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. EJSO 30: 1069-1076.
16. Warren RML, Bobrow LG, Earl HM et al (2004) Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Canc 90: 1349-1360.
17. Martincich L, Montemurro F, De Rosa G et al (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Canc Res Treat 83: 67-76.
18. Schott AF, Roubidoux MA, Helvie MA et al (2005) Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Canc Res Treat 92: 231-238.
19. Yeh E, Slanetz P, Kopans DB et al (2005) Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol 184: 868-877.
20. Belli P, Costantini M, Malaspina C et al (2006) MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 61: 946-953.
21. Segara D, Krop IE, Garber JE et al (2007) Does MRI predict pathologic tumour response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96: 474-480.
22. Kim HJ, Im Y, Han B et al (2007) Accuracy of MRI for estimating residual tumour size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol 46: 996-1003.
23. Chen JH, Feig B, Agrawal G et al (2008) MRI evaluation of pathologically complete response and residual tumours in breast cancer after neoadjuvant chemotherapy. Cancer 112: 17-26.
24. Bhattacharyya M, Ryan D, Carpenter R et al (2008) Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Canc 98: 289-293.
25. Moon HG, Han W, Lee JW et al (2009) Age and HER2 expression status affect MRI accuracy in predicting residual tumour extent after neo-adjuvant systemic treatment. Ann Oncol 20: 636-641.
26. Woodhams R, Kakita S, Hata H et al (2010) Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging-comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 254: 357-366.
27. Wright FC, Zubovits J, Gardner S et al (2010) Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer: clinical examination, mammography, or magnetic resonance imaging? J Surg Oncol 101: 604-610.
28. Park SH, Moon WK, Cho N et al (2010) Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257: 56-63.
29. De Los Santos J, Bernreuter W, Keene K et al (2011) Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. Clin Breast Cancer 11: 312-319.
30. Straver ME, Loo CE, Rutgers EJT et al (2010) MRI model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg 251: 701-707.
31. Nakahara H, Yasuda Y, Machida E et al (2011) MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes. Breast Cancer 18: 152-160.
32. Wang X, Peng W, Tan H et al (2010) Evaluation of dynamic contrast-enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Chinese-German J Clin Oncol 9: 637-642.
33. Dongfeng H, Daqing D, Erhu J (2012) Dynamic breast magnetic resonance imaging: pretreatment prediction of tumour response to neoadjuvant chemotherapy. Clin Breast Cancer 12: 94-101.
34. Fangberget A, Nilsen LB, Hole KH et al (2011) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21: 1188-1199.
35. Guarneri V, Pecchi A, Piacentini F et al (2011) Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. Ann Surg Oncol 18: 2150-2157.
36. Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29: 660-666.
37. Shin HJ, Kim HH, Ahn JH et al (2011) Comparison of mammography, sonography, MRI, and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol 84: 612-620.
38. Lyou CY, Cho N, Kim SM et al (2011) Computer-aided evaluation of breast MRI for the residual tumour extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy. Korean J Radiol 12: 34-43.
39. Chen JH, Bahri S, Mehta RS et al (2011) Breast cancer: evaluation of response to chemotherapy with 3. 0-T MR imaging. Radiology 261: 735-743.
40. Kim TH, Kang DK, Yim H et al (2012) Magnetic resonance imaging patterns of tumour regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumour cellularity. J Comput Assist Tomogr 36: 200-206.
41. Kuzucan A, Chen JH, Bahri S et al (2012) Diagnostic performance of magnetic resonance imaging for assessing tumour response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile. Clin Breast Cancer 12: 110-118.
42. Takeda K, Kanao S, Okada T et al (2012) Assessment of CAD-generated tumour volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy. Eur J Radiol 81: 2627-2631.
43. Shin HJ, Baek HM, Ahn JH et al (2012) Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS. NMR Biomed 25: 1349-1359.
44. Hylton NM, Blume JD, Bernreuter WK et al (2012) Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology 263: 663-672.
45. Park SH, Moon WK, Cho N et al (2012) Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 22: 18-25.
46. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between methods of clinical measurement. Lancet 327: 307-310.
47. Mann RM, Veltman J, Barentsz JO et al (2008) The value of MRI compared to mammography in the assessment of tumour extent in invasive lobular carcinoma of the breast. Eur J Surg Oncol 34: 135-142.
48. Berg WA, Gutierrez L, Ness Aiver MS et al (2004) Diagnostic accuracy of mammography, clinical examination, ultrasound, and MR imaging in preoperative assessment of breast cancer. Radiology 233: 830-849.
49. Cowen D, Houvenaeghel G, Bardou V et al (2000) Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer. Int J Radiat Oncol Biol Phys 47: 305-312.
50. Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138: 168-175.
51. Delille JP, Slanetz PJ, Yeh ED et al (2005) Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. The Breast J 11: 236-241.
52. Therasse P, Le Cesne A, van Glabbeke M et al (2005) RECIST versus WHO: prospective comparison of response criteria in and EORTC phase II clinical trial investigating ET-743 in advanced soft tissue carcinoma. Eur J Cancer 41: 1426-1430.
53. Park JO, Lee SI, Kim K et al (2003) Measuring response in solid tumours: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33: 533-537.
54. Kuhl CK (2009) Science to practice: why do purely intraductal cancers enhance on breast MR images? Radiology 253: 281-283.